When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?

Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-07, Vol.12 (14), p.4581
Main Authors: Marasco, Matteo, Galasso, Domenico, Larghi, Alberto, Panzuto, Francesco
Format: Article
Language:English
Subjects:
Ablation
Asymptomatic
Care and treatment
Catheters
Clinical medicine
Endoscopic ultrasonography
Methods
Pancreatic cancer
Pancreatitis
Patients
Radiofrequency ablation
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12144581